BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35110355)

  • 1. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
    Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-1BB Agonist Focuses CD8
    Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C
    Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.
    Aydin AM; Bunch BL; Beatty M; Hajiran A; Dhillon J; Sarnaik AA; Pilon-Thomas S; Poch MA
    Front Immunol; 2021; 12():628063. PubMed ID: 33717150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
    Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma.
    Ortegel JW; Staren ED; Faber LP; Warren WH; Braun DP
    Cancer Immunol Immunother; 2000 Feb; 48(11):627-34. PubMed ID: 10663610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
    Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
    Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
    Sakellariou-Thompson D; Forget MA; Hinchcliff E; Celestino J; Hwu P; Jazaeri AA; Haymaker C; Bernatchez C
    Cancer Immunol Immunother; 2019 Nov; 68(11):1747-1757. PubMed ID: 31602489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
    Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
    J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
    Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
    Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
    Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
    Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy.
    Ma Y; Ou J; Lin T; Chen L; Wang J; Qiao D; Lai S; Duan C; Cheng Y; Chang R; Zhang C; Wang M
    Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):319-329. PubMed ID: 32419542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-1BB-Enhanced Expansion of CD8
    Harao M; Forget MA; Roszik J; Gao H; Babiera GV; Krishnamurthy S; Chacon JA; Li S; Mittendorf EA; DeSnyder SM; Rockwood KF; Bernatchez C; Ueno NT; Radvanyi LG; Vence L; Haymaker C; Reuben JM
    Cancer Immunol Res; 2017 Jun; 5(6):439-445. PubMed ID: 28473315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
    Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
    Cancer Immunol Immunother; 1992; 34(4):241-51. PubMed ID: 1311218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.